Koen Vanbesien, MD
Hematology & Oncology · Cleveland, OHNPI 1073525598
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,689 of the $50,159 with a category attached, or 65.2%. 25 manufacturers reported payments, led by Gilead at 26.3% of the total. Reporting peaked in 2024 at $13,092 and has fallen 62.6% since, to $4,898 in 2025.
Across 109 payments — averaging $460.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$13K
- Daiichi Sankyo Inc.$8K
- Incyte Corporation$7K
- Pfizer$6K
- Gamida Cell Inc.$5K
- Autolus Inc$4K
- plus $8K from 19 others
Across 65 payments — averaging $13,271 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$440K
- Janssen Research & Development, LLC$324K
- Jazz Pharmaceuticals Inc.$53K
- Genmab U.S., Inc.$23K
- Novartis$22K
- National Marrow Donor Program$1K
- plus $159 from 1 others
What the payments were for
- Consulting fees$32,68965%
- Speaking & faculty fees$5,50011%
- Travel & lodging$4,3329%
- Food & beverage$3,8148%
- Education$3,8248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 21 | $13,193 |
| Daiichi Sankyo Inc. | 13 | $7,715 |
| Incyte Corporation | 18 | $6,829 |
| Pfizer | 1 | $5,500 |
| Gamida Cell Inc. | 1 | $5,000 |
| Autolus Inc | 1 | $3,750 |
| AstraZeneca | 5 | $3,008 |
| Morphosys, US Inc. | 6 | $2,470 |
| ADC Therapeutics America, Inc. | 2 | $1,200 |
| Legend Biotech USA Inc. | 2 | $259 |
| Novartis | 9 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $189 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| AbbVie | 1 | $125 |
| Sanofi | 1 | $115 |
| Bristol Myers Squibb | 4 | $112 |
| Janssen Research & Development, LLC | 2 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $74 |
| EUSA Pharma (US) LLC | 3 | $67 |
| EMD Serono, Inc. | 1 | $38 |
| Amgen | 1 | $27 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Dova Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,159 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 59 | $1,024,590 |
| RevlimidLenalidomide | 31 | $661,897 |
| NinlaroIxazomib Citrate | 25 | $326,558 |
| PomalystPomalidomide | 13 | $262,517 |
| Posaconazole | 12 | $31,667 |
| EliquisApixaban | 15 | $9,058 |
| Tacrolimus | 14 | $833 |
| Ursodiol | 12 | $831 |
| Ondansetron Hcl | 12 | $818 |
| Acyclovir | 49 | $474 |
| Prochlorperazine Maleate | 13 | $129 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $112 | $661,89731 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $189 | $326,55825 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $74 | $262,51713 claims |
| PfizerEliquis | $5,500 | $9,05815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.